Chemotherapy and immunotherapy in metastatic colorectal cancer. Pohlmann PR, Mernaugh RL, Goff LW (2009) N Engl J Med 360: 2134; author reply 2135-6 Response to Chauhan et Al.: interstitial pressure and vascular collapse in pancreas cancer-fluids and solids, measurement and meaning. DelGiorno KE, Carlson MA, Osgood R, Provenzano PP, Brockenbough JS, Thompson CB, Shepard HM, Frost GI, Potter JD, Hingorani SR (2014) Cancer Cell 26: 16-7 Eastern Cooperative Oncology Group Phase I trial of protracted venous infusion fluorouracil plus weekly gemcitabine with concurrent radiation therapy in patients with locally advanced pancreas cancer: a regimen with unexpected early toxicity. Talamonti MS, Catalano PJ, Vaughn DJ, Whittington R, Beauchamp RD, Berlin J, Benson AB (2000) J Clin Oncol 18: 3384-9 Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. Berlin JD, Catalano P, Thomas JP, Kugler JW, Haller DG, Benson AB (2002) J Clin Oncol 20: 3270-5 Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. Poplin E, Feng Y, Berlin J, Rothenberg ML, Hochster H, Mitchell E, Alberts S, O'Dwyer P, Haller D, Catalano P, Cella D, Benson AB (2009) J Clin Oncol 27: 3778-85 Full-dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pancreatic cancer: a multicenter phase II trial. Small W, Berlin J, Freedman GM, Lawrence T, Talamonti MS, Mulcahy MF, Chakravarthy AB, Konski AA, Zalupski MM, Philip PA, Kinsella TJ, Merchant NB, Hoffman JP, Benson AB, Nicol S, Xu RM, Gill JF, McGinn CJ (2008) J Clin Oncol 26: 942-7 Chemotherapy: Gemcitabine remains the standard of care for pancreatic cancer. Berlin J, Benson AB (2010) Nat Rev Clin Oncol 7: 135-7 Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial. Lennox JL, Landovitz RJ, Ribaudo HJ, Ofotokun I, Na LH, Godfrey C, Kuritzkes DR, Sagar M, Brown TT, Cohn SE, McComsey GA, Aweeka F, Fichtenbaum CJ, Presti RM, Koletar SL, Haas DW, Patterson KB, Benson CA, Baugh BP, Leavitt RY, Rooney JF, Seekins D, Currier JS, ACTG A5257 Team (2014) Ann Intern Med 161: 461-71 Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer. Nagathihalli NS, Castellanos JA, Shi C, Beesetty Y, Reyzer ML, Caprioli R, Chen X, Walsh AJ, Skala MC, Moses HL, Merchant NB (2015) Gastroenterology 149: 1932-1943.e9 Structural basis for the dual coding potential of 8-oxoguanosine by a high-fidelity DNA polymerase. Brieba LG, Eichman BF, Kokoska RJ, Doublié S, Kunkel TA, Ellenberger T (2004) EMBO J 23: 3452-61 Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Bruns CJ, Solorzano CC, Harbison MT, Ozawa S, Tsan R, Fan D, Abbruzzese J, Traxler P, Buchdunger E, Radinsky R, Fidler IJ (2000) Cancer Res 60: 2926-35 Blockade of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling for therapy of metastatic human pancreatic cancer. Baker CH, Solorzano CC, Fidler IJ (2002) Cancer Res 62: 1996-2003 Erlotinib prolongs survival in pancreatic cancer by blocking gemcitabine-induced MAPK signals. Miyabayashi K, Ijichi H, Mohri D, Tada M, Yamamoto K, Asaoka Y, Ikenoue T, Tateishi K, Nakai Y, Isayama H, Morishita Y, Omata M, Moses HL, Koike K (2013) Cancer Res 73: 2221-34 A study of 7-deaza-2'-deoxyguanosine 2'-deoxycytidine base pairing in DNA. Ganguly M, Wang F, Kaushik M, Stone MP, Marky LA, Gold B (2007) Nucleic Acids Res 35: 6181-95 Safety and pharmacokinetics of ganitumab (AMG 479) combined with sorafenib, panitumumab, erlotinib, or gemcitabine in patients with advanced solid tumors. Rosen LS, Puzanov I, Friberg G, Chan E, Hwang YC, Deng H, Gilbert J, Mahalingam D, McCaffery I, Michael SA, Mita AC, Mita MM, Mulay M, Shubhakar P, Zhu M, Sarantopoulos J (2012) Clin Cancer Res 18: 3414-27 A genome-wide association study of overall survival in pancreatic cancer patients treated with gemcitabine in CALGB 80303. Innocenti F, Owzar K, Cox NL, Evans P, Kubo M, Zembutsu H, Jiang C, Hollis D, Mushiroda T, Li L, Friedman P, Wang L, Glubb D, Hurwitz H, Giacomini KM, McLeod HL, Goldberg RM, Schilsky RL, Kindler HL, Nakamura Y, Ratain MJ (2012) Clin Cancer Res 18: 577-84 Combined blockade of Src kinase and epidermal growth factor receptor with gemcitabine overcomes STAT3-mediated resistance of inhibition of pancreatic tumor growth. Nagaraj NS, Washington MK, Merchant NB (2011) Clin Cancer Res 17: 483-93 Optimization for the blockade of epidermal growth factor receptor signaling for therapy of human pancreatic carcinoma. Solorzano CC, Baker CH, Tsan R, Traxler P, Cohen P, Buchdunger E, Killion JJ, Fidler IJ (2001) Clin Cancer Res 7: 2563-72 Administration of optimal biological dose and schedule of interferon alpha combined with gemcitabine induces apoptosis in tumor-associated endothelial cells and reduces growth of human pancreatic carcinoma implanted orthotopically in nude mice. Solorzano CC, Hwang R, Baker CH, Bucana CD, Pisters PW, Evans DB, Killion JJ, Fidler IJ (2003) Clin Cancer Res 9: 1858-67 Durability of first ART regimen and risk factors for modification, interruption or death in HIV-positive patients starting ART in Europe and North America 2002-2009. Abgrall S, Ingle SM, May MT, Costagliola D, Mercie P, Cavassini M, Reekie J, Samji H, Gill MJ, Crane HM, Tate J, Sterling TR, Antinori A, Reiss P, Saag MS, Mugavero MJ, Phillips A, Manzardo C, Wasmuth JC, Stephan C, Guest JL, Gomez Sirvent JL, Sterne JA, Antiretroviral Therapy Cohort Collaboration (ART-CC) (2013) AIDS 27: 803-13 A randomized study of emtricitabine and lamivudine in stably suppressed patients with HIV. Benson CA, van der Horst C, Lamarca A, Haas DW, McDonald CK, Steinhart CR, Rublein J, Quinn JB, Mondou E, Rousseau F, FTC-303/350 Writing Group (2004) AIDS 18: 2269-76 Effect of the vascular endothelial growth factor receptor-2 antibody DC101 plus gemcitabine on growth, metastasis and angiogenesis of human pancreatic cancer growing orthotopically in nude mice. Bruns CJ, Shrader M, Harbison MT, Portera C, Solorzano CC, Jauch KW, Hicklin DJ, Radinsky R, Ellis LM (2002) Int J Cancer 102: 101-8 Identification of novel germline polymorphisms governing capecitabine sensitivity. O'Donnell PH, Stark AL, Gamazon ER, Wheeler HE, McIlwee BE, Gorsic L, Im HK, Huang RS, Cox NJ, Dolan ME (2012) Cancer 118: 4063-73 Combined Src/EGFR Inhibition Targets STAT3 Signaling and Induces Stromal Remodeling to Improve Survival in Pancreatic Cancer. Dosch AR, Dai X, Reyzer ML, Mehra S, Srinivasan S, Willobee BA, Kwon D, Kashikar N, Caprioli R, Merchant NB, Nagathihalli NS (2020) Mol Cancer Res 18: 623-631 The use of genomic information to optimize cancer chemotherapy. Innocenti F, Cox NJ, Dolan ME (2011) Semin Oncol 38: 186-95 Development and characterization of gemcitabine-resistant pancreatic tumor cells. Shah AN, Summy JM, Zhang J, Park SI, Parikh NU, Gallick GE (2007) Ann Surg Oncol 14: 3629-37 Docetaxel/Gemcitabine followed by gemcitabine and external beam radiotherapy in patients with pancreatic adenocarcinoma. Pipas JM, Barth RJ, Zaki B, Tsapakos MJ, Suriawinata AA, Bettmann MA, Cates JM, Ripple GH, Sutton JE, Gordon SR, McDonnell CE, Perez RP, Redfield N, Meyer LP, Marshall JF, Cole BF, Colacchio TA (2005) Ann Surg Oncol 12: 995-1004 Is renal thrombotic angiopathy an emerging problem in the treatment of ovarian cancer recurrences? Kwa M, Baumgartner R, Shavit L, Barash I, Michael J, Puzanov I, Kopolovic J, Rosengarten O, Blank S, Curtin JP, Gabizon A, Muggia F (2012) Oncologist 17: 1534-40 The structures and relative stabilities of d(G x G) reverse Hoogsteen, d(G x T) reverse wobble, and d(G x C) reverse Watson-Crick base-pairs in DNA crystals. Mooers BH, Eichman BF, Ho PS (1997) J Mol Biol 269: 796-810 A novel synthesis of malondialdehyde adducts of deoxyguanosine, deoxyadenosine, and deoxycytidine. Wang H, Marnett LJ, Harris TM, Rizzo CJ (2004) Chem Res Toxicol 17: 144-9 Characterization of nucleoside and DNA adducts formed by S-(1-acetoxymethyl)glutathione and implications for dihalomethane-glutathione conjugates. Marsch GA, Mundkowski RG, Morris BJ, Manier ML, Hartman MK, Guengerich FP (2001) Chem Res Toxicol 14: 600-8 A phase I trial of CEP-701 + gemcitabine in patients with advanced adenocarcinoma of the pancreas. Chan E, Mulkerin D, Rothenberg M, Holen KD, Lockhart AC, Thomas J, Berlin J (2008) Invest New Drugs 26: 241-7 Phase I study of eniluracil, oral 5-fluororacil and gemcitabine in patients with advanced malignancy. Morgan-Meadows S, Thomas JP, Mulkerin D, Berlin JD, Bailey H, Binger K, Volkman J, Alberti D, Feierabend C, Marrocha R, Arzoomanian RZ, Wilding G (2002) Invest New Drugs 20: 377-82 Phase I study of oral irinotecan as a single-agent and given sequentially with capecitabine. Goff LW, Benson AB, LoRusso PM, Tan AR, Berlin JD, Denis LJ, Benner RJ, Yin D, Rothenberg ML (2012) Invest New Drugs 30: 290-8 Thermodynamic signature of DNA damage: characterization of DNA with a 5-hydroxy-2'-deoxycytidine·2'-deoxyguanosine base pair. Ganguly M, Szulik MW, Donahue PS, Clancy K, Stone MP, Gold B (2012) Biochemistry 51: 2018-27 Current treatment options for pancreatic carcinoma. Castellanos E, Berlin J, Cardin DB (2011) Curr Oncol Rep 13: 195-205 Chemotherapeutic advances in pancreatic cancer. Berlin JD, Rothenberg ML (2003) Curr Oncol Rep 5: 219-26 Treatment of early-stage pancreatic cancer. Castellanos EH, Cardin DB, Berlin JD (2011) Oncology (Williston Park) 25: 182-9 The role of radiation, with or without chemotherapy, in the management of NSCLC. Chakravarthy A, Johnson D, Choy H (1999) Oncology (Williston Park) 13: 93-100 A phase 1b study of erlotinib in combination with gemcitabine and nab-paclitaxel in patients with previously untreated advanced pancreatic cancer: an Academic Oncology GI Cancer Consortium study. Cohen SJ, O'Neil BH, Berlin J, Ames P, McKinley M, Horan J, Catalano PM, Davies A, Weekes CD, Leichman L (2016) Cancer Chemother Pharmacol 77: 693-701
Hints: (1) double-click or double-tap to navigate to a node. (2) Grab a node and move it to arrange the graph.